The Mutation Status of KRAS Gene Codon 12 and 13 in Colorectal Adenocarcinoma by Mastutik, Gondo et al.
Vol. 23, No. I, Nov 2016
INDONESIAN JOURNAT OF
p-ISSN 0854-4263
eISSN 4277-4685
Clinisal Pathology and
Medical Laboratory
Mojoloh Potologi Klinik lndonesio don Loborotorium Medik
IJCP & MI
(Moi. Pot. Kin.
lndonesio & Lob. Med.)
Published by lndonesion Asso ciotion ol Clinicol pothotogisls
 p-ISSN 0854-4263
Vol. 23, No. 1, November 2016 e-ISSN 4277-4685
INDONESIAN JOURNAL OF
CLINICAL PATHOLOGY AND 
MEDICAL LABORATORY
Majalah Patologi Klinik Indonesia dan Laboratorium Medik
EDITORIAL TEAM
Editor-in-chief:
Puspa Wardhani
Editor-in-chief Emeritus:
Prihatini
Krisnowati
Editorial Boards:
Maimun Zulhaidah Arthamin, AAG Sudewa, Rahayuningsih Dharma, Mansyur Arif, July Kumalawati,
Nurhayana Sennang Andi Nanggung, Aryati, Purwanto AP, Jusak Nugraha, Sidarti Soehita,
Endang Retnowati Kusumowidagdo, Edi Widjajanto, Budi Mulyono, Adi Koesoema Aman,
Uleng Bahrun, Ninik Sukartini, Kusworini Handono, Rismawati Yaswir, Osman Sianipar
Editorial Assistant:
Dian Wahyu Utami
Language Editors:
Yolanda Probohoesodo, Nurul Fitri Hapsari
Layout Editor:
Akbar Fahmi
Editorial Adress:
d/a Laboratorium Patologi Klinik RSUD Dr. Soetomo Jl. Mayjend. Prof. Dr Moestopo 6–8 Surabaya, Indonesia
 Telp/Fax. (031) 5042113, 085-733220600 E-mail: majalah.ijcp@yahoo.com, jurnal.ijcp@gmail.com
Website: http://www.indonesianjournalofclinicalpathology.or.id
Accredited No. 36a/E/KPT/2016, Tanggal 23 Mei 2016
Printed by Airlangga University Press. (OC 316/11.16/AUP-75E). Kampus C Unair, Mulyorejo Surabaya 60115, Indonesia. 
Telp. (031) 5992246, 5992247, Fax. (031) 5992248. E-mail: aup.unair@gmail.com
Kesalahan penulisan (isi) di luar tanggung jawab AUP
 p-ISSN 0854-4263
Vol. 23, No. 1, November 2016 e-ISSN 4277-4685
INDONESIAN JOURNAL OF
CLINICAL PATHOLOGY AND 
MEDICAL LABORATORY
Majalah Patologi Klinik Indonesia dan Laboratorium Medik
CONTENTS
RESEARCHS
Molecular Aspect Correlation between Glycated Hemoglobin (HbA1c), Prothrombin Time (PT) and 
Activated Partial Thromboplastin Time (APTT) on Type 2 Diabetes Mellitus (T2DM)
(Aspek molekuler Hubungan Kadar Hemoglobin Terglikasi (HbA1c), Prothrombin Time (PT) dan 
Activated Partial Thromboplastin Time (APTT) di Diabetes Melitus Tipe2 Dalam Molekuler Aspek)
Indranila KS ....................................................................................................................................................................... 1–6
Platelet-Lymphocyte Ratio (PLR) Markers in Acute Coroner Syndrome
(Platelet Lymphocyte Ratio (PLR) Sebagai Petanda Sindrom Koroner Akut)
Haerani Harun, Uleng Bahrun, Darmawaty ER ....................................................................................................... 7–11
The Mutation Status of Kras Gene Codon 12 and 13 in Colorectal Adenocarcinoma at Dr. Soetomo 
Hospital, Surabaya, Indonesia
(Status Mutasi Gen Kras Kodon 12 dan 13 pada Adenocarcinoma Kolorektal di Rumah Sakit 
Dr. Soetomo, Surabaya, Indonesia)
Gondo Mastutik, Alphania Rahniayu, Anny Setijo Rahaju, Nila Kurniasari, Reny I’tishom ....................... 12–17
Creatine Kinase to the Mortality in Myocardial Infarction
(Creatine Kinase terhadap Angka Kematian di Infark Miokard)
Liong Boy Kurniawan, Uleng Bahrun, Darmawaty Rauf, Mansyur Arif ............................................................ 18–21
Application of DNA Methylation on Urine Sample for Age Estimation 
(Penggunaan Metilasi DNA Dalam Perkiraan Umur Individu di Sampel Air Kemih)
Rosalinda Avia Eryatma, Puspa Wardhani, Ahmad Yudianto .............................................................................. 22–26
Lipid Profile Analysis on Regular and Non-Regular Blood Donors 
(Analisis Profil Lipid di Pendonor Darah Reguler dan Non-Reguler)
Waode Rusdiah, Rachmawati Muhiddin, Mansyur Arif ......................................................................................... 27–30
Percentage of CD3+ T Lymphocytes Expressing IFN-γ After CFP-10 Stimulation
(Persentase Limfosit T-CD3+ yang Mengekspresikan Interferon Gamma Setelah Stimulasi Antigen 
CFP-10)
Yulia Nadar Indrasari, Betty Agustina Tambunan, Jusak Nugraha .................................................................... 31–35
Characteristics of Crossmatch Types in Compatibility Testing on Diagnosis and Blood Types Using 
Gel Method
(Ciri Tipe Inkompatibilitas Uji Cocok Serasi Metode Gel terhadap Diagnosis dan Golongan Darah)
Irawaty, Rachmawati AM, Mansyur Arif .................................................................................................................... 36–41
Diagnostic Values of Mycobacterium Tuberculosis 38 kDa Antigen in Urine and Serum of Childhood 
Tuberculosis
(Nilai Diagnostik Antigen 38 kDa Mycobacterium tuberculosis Air Kemih dan Serum di Tuberkulosis 
Anak)
Agustin Iskandar, Leliawaty, Maimun Z. Arthamin, Ery Olivianto ..................................................................... 42–49
Thanks to editors in duty of IJCP & ML Vol 23 No. 1 November 2016
Kusworini Handono, Prihatini, Purwanto AP, July Kumalawati, Jusak Nugraha, Ida Parwati, 
Adi Koesoema Aman, Edi Widjajanto, AAG. Sudewa, Nurhayana Sennang AN 
Erythrocyte Indices to Differentiate Iron Deficiency Anemia From β Trait Thalassemia
(Indeks Eritrosit Untuk Membedakan Anemia Defisiensi Besi Dengan Thalassemia β Trait)
Yohanes Salim, Ninik Sukartini, Arini Setiawati ..................................................................................................... 50–55
HbA1c Levels in Type 2 Diabetes Mellitus Patients with and Without Incidence of Thrombotic Stroke
(Kadar HbA1c Pasien Diabetes Mellitus Tipe 2 Dengan dan Tanpa Kejadian Strok Infark Trombotik)
Dafina Balqis, Yudhi Adrianto, Jongky Hendro Prayitno ...................................................................................... 56–60
Comparative Ratio of BCR-ABL Genes with PCR Method Using the Codification of G6PD and ABL 
Genes in Chronic Myeloid Leukemia Patients
(Perbandingan Angka Banding Gen BCR-ABL Metode PCR Menggunakan Baku Gen Glucosa-6-
Phosphate Dehidrogenase dan Gen Abelson Kinase di Pasien Chronic Myeloid Leukemia)
Tonggo Gerdina Panjaitan, Delita Prihatni, Agnes Rengga Indrati, Amaylia Oehadian .............................. 61–66
Virological and Immunological Response to Anti-Retroviral Treatment in HIV-Infected Patients
(Respons Virologis dan Imunologis Terhadap Pengobatan Anti-Retroviral di Pasien Terinfeksi HIV) 
Umi S. Intansari, Yunika Puspa Dewi, Mohammad Juffrie, Marsetyawan HNE Soesatyo, 
Yanri W Subronto, Budi Mulyono ................................................................................................................................ 67–73
Comparison of slLDL-C Analysis Using Srisawasdi Method and Homogeneous Enzymatic Assay 
Method on Hypertriglyceridemia Condition 
(Perbandingan Analisa sdLDL-C metode Srisawasdi dan Homogeneous Enzymatic Assay di Kondisi 
Hipertrigliseridemia)
Gilang Nugraha, Soebagijo Poegoeh Edijanto, Edhi Rianto ................................................................................. 74–79
Pattern of Bacteria and Their Antibiotic Sensitivity in Sepsis Patients 
(Pola Kuman dan Kepekaan terhadap Antibiotik di Pasien Sepsis) 
Wahyuni, Nurahmi, Benny Rusli .................................................................................................................................. 80–83
The Correlation of Naive CD4+T Lymphocyte Cell Percentage, Interleukin-4 Levels and Total 
Immunoglobulin E in Patients with Allergic Asthma
(Kenasaban antara Persentase Sel Limfosit T-CD4+ Naive dengan Kadar Interleukin-4 dan Jumlah 
Imunoglobulin E Total di Pasien Asma Alergi)
Si Ngr. Oka Putrawan, Endang Retnowati, Daniel Maranatha ............................................................................ 84–89
LITERATURE REVIEW
Antibiogram
(Antibiogram)
Jeine Stela Akualing, IGAA Putri Sri Rejeki .............................................................................................................. 90–95
CASE REPORT
Pancreatic Cancer in 31 Years Old Patient with Normal Serum Amylase Level
(Kanker Pankreas di Pasien Usia 31 Tahun Dengan Kadar Amilase Serum Normal)
Melda F. Flora, Budiono Raharjo, Maimun Z. Arthamin ........................................................................................ 96–101
12
2016 Nov; 23(1): 12–17
p-ISSN 0854-4263 | e-ISSN 4277-4685
Available at www.indonesianjournalofclinicalpathology.or.id
RESEARCH
THE MUTATION STATUS OF KRAS GENE CODON 12 AND 13 IN 
COLORECTAL ADENOCARCINOMA AT DR. SOETOMO HOSPITAL, 
SURABAYA, INDONESIA
(Status Mutasi Gen Kras Kodon 12 dan 13 pada Adenocarcinoma Kolorektal di 
Rumah Sakit Dr. Soetomo, Surabaya, Indonesia)
Gondo Mastutik1, Alphania Rahniayu1, Anny Setijo Rahaju1, Nila Kurniasari1, Reny I’tishom2
ABSTRAK
Kanker kolorektum merupakan salah satu kanker yang tersering di dunia. Target molekuler untuk pengobatan kanker kolorektum 
yaitu epidermal growth factor receptor (EGFR) dengan pemberian antibodi monoklonal anti-EGFR. Pemberian pengobatan ini tidak 
dapat memberikan efek di pasien dengan status gen KRAS bentuk mutan, sehingga perlu dilakukan pemeriksaan status mutasi gen KRAS. 
Telitian berupa deskriptif dengan pendekatan potong lintang yang bertujuan untuk mendapatkan data status mutasi gen KRAS kodon 
12 dan 13 di pasien adenocarcinoma colorectal. Deteksi mutasi KRAS dilakukan dengan teknik Polymerase Chain Reaction Restriction 
Fragment Length Polymorphism (PCR RFLP) yang dikonfirmasi dengan sekuensing. Sampel telitian adalah 30 blok parafin yang diperoleh 
dari Rumah Sakit Dr.Soetomo Surabaya masa waktu Januari-Desember 2013. Setelah dilakukan ekstraksi DNA terdapat 21 sampel yang 
dapat digunakan untuk pemeriksaan lanjutan. Hasil PCR RFLP menunjukkan terdapat 7/21 mutasi pada kodon 12 dan tidak terdapat 
mutasi gen KRAS pada kodon 13. Mutasi pada kodon 12 yaitu GGT>GCT, GGT>GGA dan GGT>GAT yang menyebabkan perubahan 
asam amino Gly12Ala, Gly12Gly dan Gly12Asp. Simpulan telitian ini adalah mutasi gen KRAS kodon 12 pada adenocarcinoma colorectal 
di Rumah Sakit Dr. Soetomo Surabaya sebanyak 33%. 
Kata kunci: Adenocarcinoma colorectal, PCR RFLP, KRAS
ABSTRACT
Colorectal cancer is one of the most common cancers in the world. The molecular target for treatment of colorectal cancer is 
epidermal growth factor receptor (EGFR) by anti-EGFR monoclonal antibody. Treatment with anti-EGFR antibody in patients with 
KRAS gene mutation had no effect, so it is necessary to check the mutation status of the KRAS gene. This study was a descriptive 
study with a cross sectional approach aimed to obtain the mutation status of KRAS gene in colorectal adenocarcinoma. Detection of 
KRAS mutations was done by using Restriction Fragment Length Polymorphism Polymerase Chain Reaction (RFLP PCR) confirmed by 
sequencing. The samples were 30 paraffin blocks obtained from the Dr.Soetomo Hospital during January-December 2013. After DNA 
extraction there were 21 samples that could be used for further examination. RFLP PCR Results showed 7/21 mutation in Kras gene 
codon 12 and no mutation in codon 13. Mutations in codon 12 were as follows GGT>GCT, GGT>GGA and GGT>GAT that changed 
amino acid Gly12Ala, Gly12Gly, and Gly12Asp. In conclusion, the mutation of codon 12 KRAS gene in colorectal adenocarcinoma at 
the Dr. Soetomo Hospital Surabaya was 33%.
Key words: Adenocarcinoma colorectal, PCR RFLP, KRAS
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INTRODUCTION
Colorectal cancer (CRC) is one of the most common 
cancers in the world. In 2013 approximately 102,480 
cases of colon cancer and 40,340 cases of rectal 
cancer were diagnosed in the United States.1 About 
608,000 deaths from CRC are estimated worldwide, 
accounting for 8% of all cancer deaths, making it the 
fourth most common cause of death from cancer. The 
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age-standardized incidence rates of CRC per 100.000 
populations in Indonesia were 15.9 for males (the 
second most cancer after lung cancer for men) and 
10.1 for females (the third most cancer after breast 
and cervix uterin cancer).2
An important molecular target for the treatment 
of CRC is the epidermal growth factor receptor 
(EGFR) using monoclonal anti-EGFR antibody, 
cetuximab and panitumumab. Anti-EGFR binds to 
EGFR and phosphorylated EGFR to prevent and block 
ligand activation-induced EGFR tyrosine kinase, 
thereby preventing the activation of downstream 
signaling pathways PI3K and RAS/MEK/ERK. This 
results in cellular proliferation and induces barriers 
apoptosis.3,4
Kirsten rat sarcoma-2 virus oncogene (KRAS) 
protein is one of the most important molecules in 
the EGFR downstream signaling pathway. KRAS 
gene, also called p21, encodes a small G-protein 
that functions as downstream of EGFR-induced cell 
signaling.4,5 When the EGF or other ligands occupy 
the EGFR, it activates a signaling cascade via several 
pathways, including the RAS-RAF-mitogen-activated 
protein kinase (MAPK) and phosphoinositide 3-kinase 
(PI3K)-AKT pathways, which control cell proliferation, 
differentiation, and survival.5 RAS proteins normally 
cycle between active (RAS-GTP) and inactive (RAS-
GDP) conformations. RAS proteins are activated by 
guanine nucleotide exchange factors (GEFs) which 
are recruited to protein complexes at the intracellular 
domain of activated receptors. Signaling is terminated 
when RAS-GTP is hydrolyzed to the RAS-GDP inactive 
complex by GTPase-activating proteins (GAPs). Under 
physiological conditions, levels of RAS-GTP in vivo are 
tightly controlled by the counterbalancing activities of 
GEFs and GAPs.6 Mutations in genes that encode RAS 
proteins disrupt this balance, causing perturbations 
in downstream signaling activities. These KRAS gene 
mutations result in RAS proteins that are constitutively 
in the active RAS-GTP conformation. Unlike wild-type 
RAS proteins which are deactivated after a short time, 
the mutated RAS proteins cause continuous activation 
of RAS signaling pathways in the abscence of upstream 
stimulation of EGFR/HER receptors. This oncogenic 
activation of RAS signaling pathways has been 
implicated in many aspects of the malignant process, 
including abnormal cell growth, proliferation, and 
differentiation.6
The KRAS gene mutations occur in about 35-40% 
of CRC. This mutation is a single nucleotide point 
mutation in codons 12, 13 and 61. This mutation 
occurs during the development of CRC carcinogenesis. 
Approximately 17–25% of all cancers have mutations 
in the KRAS gene and 30–40% of CRC.7 KRAS gene 
mutations were found in exon 2 at codon 12 and codon 
13 which is about 85-90% and at codon 61 (5%) and 
146 (5%).4
The KRAS gene mutations have an impact on the 
selection of therapy in patients with CRC. Several 
studies have reported that KRAS mutations caused 
resistance to anti-EGFR monoclonal antibody. KRAS 
mutations were associated with poor response to 
therapy. KRAS gene mutations lead to the activation 
of downstream signaling pathways without stimulation 
upstream of the receptor EGFR/HER so that therapy 
with monoclonal anti-EGF antibody as a ligand of 
EGFR becomes useless.5,6 Although EGFR ligand bound 
with monoclonal anti-EGF antibody, activation of cell 
proliferation pathways continue so that the cell number 
is increasing. Based on this, it is necessary determine 
the status of the KRAS gene mutations in codons 12 
and 13 in patients with colorectal adenocarcinoma in 
the Dr. Soetomo Hospital. 
METHODS
This study was an observational study with cross 
sectional approach to determine the status of the 
KRAS gene mutations in patients with colorectal 
adenocarcinoma who underwent histopathologic 
examination at the Department of Pathology School of 
Medicine, Airlangga University-Dr. Soetomo Hospital 
in Surabaya from January to December 2013. The 
study has been approved by the Health Research 
Ethics Committee of the School of Medicine, Airlangga 
University No. 348/EC/KEPK/FKUA/2014.
The inclusion criteria of samples were 
histopathology examination conducted at the 
Department of Pathology Dr. Soetomo Hospital, 
microscopic appearance in accordance with the criteria 
of colorectal adenocarcinoma, and tissue in paraffin 
blocks which was still fairly representative for the 
purpose of this research. Exclusion criteria for samples 
was not enough tissue in paraffin blocks for research 
purposes. 
Paraffin blocks with the inclusion criteria 
were taken for the DNA extraction randomly. The 
preparation process of paraffin blocks was conducted 
as previous studies.8 Paraffin blocks are cut to the 
size of 25 μm (5 μm × 5 μm pieces). Microtome knife 
before being used to cut blocks of paraffin was washed 
with 20% chlorox bleach to avoid DNA contamination, 
then washed with detergent, rinsed with clean 
water, dried, and cleaned with absolute ethanol. 
Deparaffination was done by xylol and rehydration 
with ethanol. DNA extracted by QIAamp Tissue DNA 
Mini Kit (Qiagen) was done in accordance with the 
manual use of reagents and subsequently used as a 
template for polymerase chain reaction (PCR).
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Detection of KRAS gene mutations in codons 12 
and 13 was performed by Restriction Fragment Lengh 
Polymorphisme (RFLP) PCR as in a previous research. 
Primers used to detect mutations in codon 12, namely 
forward primer 5’-ACT GAA TAT AAA CTT GTA GTG 
GTT CCT GGA-3’, reverse primer 5’-CTG TAT CAA AGA 
ATG GTC CAG CTG CAC TA-3’ which produced162 
base pair (bp). Restrictions to determine the mutation 
of KRAS gene codon 12 used MvaI enzyme. The 
wildtype KRAS gene may be restricted to one location 
which produced two fragments, namely the size of 133 
bp and 29 bp, while the mutant KRAS gene was not 
restricted resulting in a 162 bp fragment.9
Primers used to detect mutations in codon 13, 
namely forward primer 5’-GTA CTG GTG GAG GTG 
ATA TAT TAT TAA TTG-3’ and reverse primer 5’-GTA 
AGG TCG TCA CAC CTA TGC TCT GG-3’ that produced 
159 bp. Restrictions to determine the mutation 
of KRAS gene codon 13 used BsuRI enzyme. The 
wildtype KRAS gene can be restricted in two locations 
locations producing three fragments of DNA which was 
measured 85 bp, 48 bp and 26 bp, while the mutant 
KRAS gene may be restricted to one location so as to 
produce two fragments which was measured 85 bp 
and 74 bp.9
The PCR composition were the master mix 
10 μl, dH2O 5 μl, forward primer 1 μl, reverse primer 
1 μl, samples of 5 μl. The PCR conditions were 
predenaturation at 94°C for 5 minutes, denaturation 
94°C for 1 minute, annealing 63°C for 1 minute, 
extention 72°C for 30 seconds, 40 cycles and a final 
extension 72°C for 10 minutes. Electrophoresis 
used agarose 4% which was then visualized by gel 
documentation. PCR RFLP with positive results were 
confirmed by sequencing using ABIPRISM 310. 
RESULTS AND DISCUSSION
In the year 2013, 139 colon and rectum neoplastic 
lession were registered, with mean age (range 26-82 
years old, males 74, females 65). The majority were 
histopathologically classified as carcinoma 85.61% and 
the rest was adenoma 5.03%, non epithelial tumors 
5.76%, and secondary tumours 3.6%. 
This study used 30 paraffin blocks from patients 
aged 28–68 years. The most age was 41–50 years 
(9/30), age 51–60 years (7/30), age 61–70 years 
(6/30) and 31–40 years (6/30), age 28–30 years 
(2/30) of patients. Males were 18 and females were 
12 patients. 
The samples of this study used were the tumor 
tissues in the paraffin blocks. The tumor tissues 
were fixed with buffer formalin, and processed with 
formalin, alcohol, xylol, and paraffin, then the tumor 
tissues were embedded in the block of paraffin, 
called formalin fixed paraffin embedded (FFPE). 
Gold standard to analyze the Kras gene mutation is 
using specimen from the frozen tissue.10 However, 
routine procedures to diagnose the tumor tissue were 
performed by buffered formalin fixation, so that the 
tumor tissue was not stored in frozen tissue form 
but in the paraffin block. DNA extraction from FFPE 
samples had a poor quality of DNA.10 This was because 
the tumor tissues had undergone processing with the 
addition of alcohol, xylol, and paraffin blocks, causing 
fragmention to DNA. This was consistent with the 
results of this research using 30 paraffin blocks but 9 
blocks could not be used for the PCR process, so there 
were only 21 blocks that can be used for the detection 
of the KRAS gene mutations.
Identification of the KRAS gene mutation at codon 
12 used primers KRAS 12F/R produced 162 bp and 
KRAS 13F/R products 159 bp (Figure 1). Detection of 
KRAS gene mutations in this study was conducted by 
RFLP PCR, is a PCR technique to amplify DNA in PCR 
reaction, then the PCR product was restricted (cut) into 
multiple fragments of DNA using restriction enzymes. 
Restriction enzymes in this study used MvaI enzyme 
(also called BstNI) and BsuRI (also called HaeIII). Side 
restriction enzyme MvaI side was CCWGG, W was 
(a) (b)
Figure 1. The identification of KRAS gene at codon 12 produced 162 bp (a) and codon 13 produced 159 bp (b).
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nucleotide A/T, while the restriction enzyme BsuRI 
was GGCC. 
The PCR products were purified to clean the PCR 
products from the remaining PCR reagents so the restriction 
enzyme easily recognized the recognition sequences 
contained in the PCR product. After obtaining the pure 
DNA product from the codon 12 and 13, then restriction 
was carried out. Restriction reaction composition consisted 
of nuclease free water 16 μL, 10 × buffer R 2 μL, 1 μL 
pure DNA product and MvaI enzyme 1 μL, then it was 
incubated at a temperature of 60°C for 16 hours. The 
restriction reaction product was then electrophorized using 
low melting agarose 4%.
The MvaI enzyme recogniced the codon 12 PCR 
products at one location. If the wild type KRAS 
gene was restricted at one location resulting in two 
fragments of DNA with a size of 133 bp and 29 bp, 
if the mutant KRAS gene was not restricted, thus 
resulting in a 162 bp fragment (Figure 2, 4). The BsuRI 
enzyme recognized the codon 13 PCR product at two 
locations. The wild type KRAS gene was restricted at 
two locations resulting in three fragments of DNA with 
a size of 85 bp, 48 bp and 26 bp, while the mutant 
KRAS gene was then restricted at one location so as to 
produce 85 bp and 74 bp (Figures 3, 4).
The results of RFLP PCR with MvaI enzyme at 
codon 12 showed that the mutation of KRAS gene at 
codon 12 was found to be 33% (7/21) mutations and 
67% (14/21) wild type. The restriction enzyme BsuRI 
at the codon 13 of KRAS gene showed that there was 
no mutation of KRAS gene. The KRAS gene at codon 
13 in all samples in this study was a wild type (Table 
1). The results were then confirmed by sequencing. 
The sequencing results also showed similar results 
with the results of RFLP PCR. Based on the results of 
sequencing it was known that mutations occurring at 
codon 12 were GGT>GAT, GGT>GCT and GGT>GGA 
Figure 2. Restriction of the codon 12 PCR product with 
MvaI enzyme, producing 162 bp at the mutant 
type (D,E) and 133 bp, 29 bp at wild type 
(A,B,C,F,G) KRAS gene, H=marker.
Figure 3. Restriction of the codon 13 PCR product with 
BsuRI enzyme, producing 85 bp, 48 bp and 26 bp 
at the wild type, 85 bp and 74 bp at the mutant 
type of KRAS gene.
Figure 4. Restriction with Mva at the codon 12 PCR product 
and BsuRI at the codon 13 PCR product. B, 
F=marker, A,C,D,E= the codon 12 PCR product, 
162 bp (C), wildtype (A) and mutant type 
heterozygote (D,E) (mutant type produced band 
162 bp, wild type produced band 133 bp and 29 
bp, band 29 bp invisible). G,H,I = the codon 13 
PCR product, 159bp (G), wildtype (H,I) (wild 
type produced band 85 bp, 48 bp and 26 bp, 
mutan type produced band 85 bp and 74 bp). 
Table 1. The mutation status of KRAS gene at colorectal 
adenocarcinoma 
No Type Tissue 
The type of 
codon 12 
mutation 
1 Adenoca Well Diff Rectosigmoid GGT>GAT 
2 Adenoca Well Diff Colon GGT>GCT
3 Mucinus Adenoca Rectum GGT>GGA
4 Adenoca Well Diff Rectum GGT>GGA
5 Adenoca Well Diff Rectum GGT>GAT
6 Adenoca Poor Diff Anorectum GGT>GAT
7 Adenoca Moderate 
Diff
Rectum GGT>GCT
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(Figure 5). This mutation caused an amino acid change 
in Gly12Ala, Gly 12 Gly and Gly12Asp.11 
KRAS gene families include RAS (KRAS, NRAS, 
HRAS) located on chromosome 12, consisting of four 
exons and encodes 189 amino acid.10 KRAS gene 
encodes a protein guanosine-5-triphosphate (GTP)-
binding which is an effector important for ligand-
bound EGFR.4 Results of this study showed that 
mutation of the KRAS gene codon 12 were GGT>GAT, 
GGT>GCT, and GGT>GGA which caused amino acid 
changes Gly12Ala, Gly 12 Gly and Gly12Asp.
KRAS gene mutations in CRC were found in 30-
40% of patients, that is 85-90% occurring in exon 2 
codon 12 and 13.5% at codon 61 and codon 146.4,7 
KRAS gene mutation was found in 31% of the 1989 
cancer colorectal cases and this mutation was 
significantly associated with lower survival rates 
compared with wild type.12 KRAS KRAS gene mutation 
was commonly found in the form of point mutations, 
G12D, G12A, G12R, G12C, G12S, G12V and G13D.11 
Mutation at codon 12, pG12D and pG12V was the 
most frequent, whereas mutations were often found at 
codon 13, pG13D.10 KRAS gene mutations in codons 
12 and 13 play an important role in the progression of 
colorectal cancer and mutations in codons 12, 13 and 
61 is a biomarker for lung cancer.6
These mutations impair the intrinsic GTPase activity 
of KRAS and prevent GAPs from promoting GTP 
hydrolysis by KRAS, therefore causing KRAS proteins 
to accumulate in the GTP-bound, active form. In this 
manner, mutant KRAS results in a constitutively active 
GTP-bound state and the activation of downstream 
pro-proliferative signaling pathways. Therefore, KRAS 
mutations play a critical role in human tumor genesis 
and are the most prevalent in pancreatic, thyroid, 
colorectal and lung cancers.10
The results of the research groups Kirsten Ras 
in the Colorectal Cancer Collaborative Group Study 
(RASCAL Study)12 of 2,721 patients with colorectal 
cancer who came from 13 countries, showed that 
KRAS gene cases increases the risk of recurrence and 
death, especially mutation guanine (G) into Thymine 
(T). Such mutations are not associated with sex, age, 
large tumor, or Dukes’ stage. Type of cancer with 
poorly differentiated rarely mutated KRAS. RASCAL 
II Study revealed that KRAS mutations occur in the 
development of pre-cancerous adenomas in the colon 
and rectum. Mutation glycine to valine becomes 
important to determine the progression of cancer and 
also predispose to cancer to become more aggressive 
evolved into advanced colorectal cancer.13
KRAS mutations have also been associated with 
more rapid and aggressive metastatic behavior of 
colorectal liver metastases. KRAS mutation and high 
Ki-67 expression were associated with multiple liver 
metastases, shorter time interval to their detection; and 
with poor survival after colon resection. Additionally, 
KRAS mutation was independently associated with 
poor survival after liver resection. KRAS C12V 
mutations were more frequently associated with 
hepatic metastasis. Further, in a recent study of 143 
Korean patients with metastatic or recurrent colorectal 
cancer, lung metastasis was more frequently the initial 
metastatic site in patients with the KRAS mutations.7 
There is evidence in multiple randomized trials 
of improved response rate, progression free survival 
and/or overall survival in response to anti-EGFR MoAb 
therapy only in patients with no mutations in codon 
12 or 13 versus mutated KRAS tumors. Since then, 
KRAS mutations have emerged as a major predictor of 
resistance to EGFR inhibitors in first-line as well as in 
subsequent lines of treatment. The American Society 
of Clinical Oncology (ASCO) recently published their 
provisional clinical opinion that patients with mCRC, 
having a KRAS mutation in codon 12 or 13, should not 
receive anti-EGFR antibody treatment.7 
CONCLUSION AND SUGGESTION 
The conclusion of this study is that the KRAS gene 
mutation from paraffin blocks of the colon and rectum 
adenocarcinoma patients in the Dr. Soetomo Hospital 
obtained 33% (7/21), which occurred at codon 12 is 
GGT>GCT, GGT>GGA and GGT>GAT causing amino 
acid changes Gly12Ala, Gly12Gly and Gly12Asp and 
there was no mutation at codon 13.
Suggestion of this study is the identification of 
the KRAS gene mutation status can be performed on 
Figure 5. Part sequence of the mutant type of KRAS gene 
at GGT>GCT, GGT>GGA, GGT>GAT 
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all types of malignancy of the tumor solid tissues to 
determine the targeted therapy of malignancy. 
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